Forian Completes Take-Private Merger and Nasdaq Delisting

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Forian ( (FORA) ) has issued an announcement. On May 15, 2026, Forian Inc. completed a cash tender offer and subsequent merger with 2025 Acquisition Company, LLC, after Bravo Merger Sub, Inc. acquired all outstanding shares not already owned by the buyer group at $2.17 per share. The transaction, which followed an offer that expired on May 14, 2026 with approximately 91% of shares tendered, resulted in Forian becoming a wholly owned subsidiary of the acquisition vehicle. In connection with the deal’s closing on May 15, 2026, Forian moved to delist its common stock from the Nasdaq Capital Market and deregister under the Securities Exchange Act, ending its public reporting obligations. The merger also triggered the conversion or cancellation of equity awards and a board shake-up, leaving Max Wygod as the sole director and effectively transitioning Forian into a privately held company. The most recent analyst rating on (FORA) stock is a Hold with a $2.10 price target. To see the full list of analyst forecasts on Forian stock, see the FORA Stock Forecast page. Spark’s Take on FORA Stock According to Spark, TipRanks’ AI Analyst, FORA is a Neutral. Score is held back primarily by weak financial performance (steep TTM revenue decline and ongoing losses). The take-private transaction improves the outlook by offering a clearer near-term value realization, while technicals are mildly supportive; valuation is constrained by negative earnings and no dividend data. To see Spark’s full report on FORA stock, click here. More about Forian Forian Inc. is a data analytics and information solutions provider serving traditional and emerging life sciences companies, healthcare payers and providers, and clients in the financial services industry. The company specializes in acquiring, integrating and commercializing large-scale healthcare data assets, layering data science tools over a comprehensive clinical data lake to deliver performance-focused insights. Average Trading Volume: 29,518 Technical Sentiment Signal: Buy Current Market Cap: $67.79M